Valuation: Cogstate Limited

Market Cap 425M 299M 259M 242M 222M 420M 28.41B 2.85B 1.11B 14.2B 1.12B 1.1B 47.06B P/E 2026 *
25.4x
P/E 2027 * 18.7x
Enterprise Value 368M 258M 224M 209M 192M 364M 24.59B 2.47B 964M 12.29B 971M 949M 40.72B EV / Sales 2026 *
4.23x
EV / Sales 2027 * 3.45x
Free-Float
54.18%
Yield 2026 *
1.31%
Yield 2027 * 1.64%

Last Transcript: Cogstate Limited

1 day-8.57%
1 week-8.57%
Current month-8.57%
1 month-11.11%
3 months-9.09%
6 months+10.34%
1 week 1.6
Extreme 1.6
1.6
1 month 1.6
Extreme 1.6
1.99
Current year 1.26
Extreme 1.26
1.99
1 year 1
Extreme 1
2.1
3 years 0.55
Extreme 0.553
2.1
5 years 0.55
Extreme 0.553
2.1
10 years 0.14
Extreme 0.14
2.1
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 17/12/1999
Chief Executive Officer - 01/12/2005
Director of Finance/CFO - 01/02/2021
Director TitleAgeSince
Director/Board Member - 01/03/2011
Chairman 67 03/11/2009
Director/Board Member - 20/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
-8.57%-8.57% - - 298M
-0.68%-0.68%-1.63%+12.86% 48.22B
+6.03%+5.22%+420.33%+519.87% 38.79B
-2.21%-6.07%+24.87%+5.20% 38.41B
+2.94%-2.25%+6.15%+59.69% 34.88B
+1.98%+4.74%+12.19%+41.37% 29.19B
+0.31%+0.72%+32.99%+122.25% 16B
+0.47%-3.87% - - 16.05B
+1.59%+0.44%+3.43%+16.80% 13.53B
-0.98%-12.98%-4.82%-38.09% 12.22B
Average +0.09%+0.01%+61.69%+92.49% 27.48B
Weighted average by Cap. +1.20%+1.55%+78.99%+112.40%

Financials

2026 *2027 *
Net sales 86.95M 61.14M 53.09M 49.5M 45.47M 86M 5.82B 584M 228M 2.91B 230M 225M 9.63B 102M 71.91M 62.44M 58.22M 53.48M 101M 6.84B 686M 268M 3.42B 270M 264M 11.33B
Net income 16.9M 11.88M 10.32M 9.62M 8.84M 16.72M 1.13B 113M 44.34M 565M 44.63M 43.65M 1.87B 22.92M 16.12M 14M 13.05M 11.99M 22.67M 1.53B 154M 60.15M 767M 60.54M 59.21M 2.54B
Net Debt -57.17M -40.2M -34.91M -32.55M -29.9M -56.55M -3.82B -384M -150M -1.91B -151M -148M -6.33B -72.31M -50.85M -44.15M -41.17M -37.82M -71.53M -4.84B -485M -190M -2.42B -191M -187M -8.01B
Logo Cogstate Limited
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
Employees
160
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.500AUD
Average target price
3.540AUD
Spread / Average Target
+41.60%

Quarterly revenue - Rate of surprise